Skip To Main Content
H. Tilly on Muck Rack

H. Tilly

As seen in: Wiley Online Library, The New England Journal of Medicine, Annals of Oncology
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile
Back to H. Tilly’s profile

Articles by H. Tilly

Pola‐R‐CHP versus R‐CHOEP in young patients with high‐risk diffuse large B‐cell lymphoma

|
By G. Lenz, H. Tilly, M. Ziepert, B. Altmann
| Wiley Online Library Verified
Introduction: The best treatment for young patients with high-risk diffuse large B-cell lymphoma (DLBCL) is still a matter of debate. Results of the phase 3 R-MegaCHOEP study showed promising results using etoposide in combination with R-CHOP (R-CHOEP). Progression-free (PFS) and overall survival (OS) rates for young patients (18–60 years) with high-risk (age-adjusted IPI 2, 3) DLBCL treated with R-CHOEP were among the best reported for such patients.
Open in Who Shared Issue with article?

Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

|
By H. Tilly, université de Rouen, U. Vitolo, A. Jack, M. Meignan
| Annals of Oncology Verified
Diffuse large B-cell lymphoma (DLBCL) constitutes 30%–58% of non-Hodgkin's lymphoma series. The crude incidence in Europe is 3.8/100 000/year [1]. The incidence increases with age and varies considerably across Europe. A family history of lymphoma, autoimmune disease, human immunodeficiency virus (HIV) infection, hepatitis C virus (HCV) seropositivity, a high body mass as a young adult and some occupational exposures have been identified as risk factors of DLBCL [2].
Open in Who Shared Issue with article?

Inhibition of Hedgehog signaling for the treatment of lymphoma and CLL: a phase II study from the LYSA

|
By R. Houot, CHU Rennes, C. Soussain, H. Tilly, C. Haioun
| Annals of Oncology Verified
Hedgehog (Hh) signaling pathway orchestrates numerous processes throughout embryogenesis. Although the pathway seems inactive or dispensable in most adult tissues, it becomes reactivated in a wide range of cancers [1]. For this reason, blockade of the Hedgehog pathway could yield promise in the treatment of cancer [2, 3]. Several Hh pathway inhibitors (HPIs) are currently under clinical development. Vismodegib (Genentech-Curis) is the first-in-class HPI approved in the clinic.
Open in Who Shared Issue with article?

Effect of Hydroxyurea on the Frequency of Painful Crises in Sickle Cell Anemia

|
By H. Tilly, S.R. Ytterberg, R.L. Gottlieb
| The New England Journal of Medicine Verified
37 References 1477 Citing Articles Letters Related Articles Abstract Background In a previous open-label study of hydroxyurea therapy, the synthesis of fetal hemoglobin increased in most patients with sickle cell anemia, with only mild myelotoxicity. By inhibiting sickling, increased levels of fetal hemoglobin might decrease the frequency of painful crises.
Open in Who Shared Issue with article?
Show More